Business
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
Shield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nShield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC).\n\n\nThe ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode) study is an over 20,000 patient registrational study evaluating the performance of the Shield blood test for detecting CRC in average-risk adults. The data presented at DDW elaborates on the top-line data the company announced in December 2022. Data presented today include:\n\n\n\n83% sensitivity in detecting individuals with CRC;\n\n\n\n81% sensitivity in detecting Stages I-III;\n\n\n\n72% sensitivity in detecting localized disease (Stage I-II); and\n\n\n\nSensitivity by stage of 55% for Stage I, 100% for Stage II, 100% for Stage III, and 100% for Stage IV.\n\n\n\nThese results are in range with other guideline recommended non-invasive screening modalities, where overall sensitivity ranges from 74-92%.\n\n\nThe ability to detect cancers in early stages is an important test parameter as the five-year survival rate is higher when caught early.1 Shield’s sensitivity of detecting stage I-III cases and localized cases (stage I-II) is in range with other guideline-recommended non-invasive screening modalities (FIT sensitivity in Stage I-III is 73%, and in localized cases is 70%).2\n\n\n“There is a need for a more convenient and less invasive method to screen for colorectal cancer, and an accurate blood test has the potential to overcome many barriers patients face with traditional screening methods,\" said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. \"The data presented today at DDW highlight the promising results for blood-based CRC screening and the potential for blood tests to help close the gap in screening adherence.\"\n...